Marizyme Stock Fundamentals
| MRZM Stock | USD 0.04 0.01 20.00% |
Marizyme fundamentals help investors to digest information that contributes to Marizyme's financial success or failures. It also enables traders to predict the movement of Marizyme OTC Stock. The fundamental analysis module provides a way to measure Marizyme's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Marizyme otc stock.
Marizyme |
Marizyme OTC Stock Return On Asset Analysis
Marizyme's Return on Asset or ROA shows how effective is the management of the company in generating income from utilizing all of the assets at their disposal. It is a useful ratio to evaluate the performance of different departments of a company as well as to understand management performance over time.
Current Marizyme Return On Asset | -0.15 |
Most of Marizyme's fundamental indicators, such as Return On Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Marizyme is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Return on Asset measures overall efficiency of a company in generating profits from its total assets. It is expressed as the percentage of profits earned per dollar of Asset. A low ROA typically means that a company is asset-intensive and therefore will needs more money to continue generating revenue in the future.
| Competition |
Based on the latest financial disclosure, Marizyme has a Return On Asset of -0.1468. This is 98.32% lower than that of the Software sector and 99.38% lower than that of the Information Technology industry. The return on asset for all United States stocks is 4.86% higher than that of the company.
Marizyme Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Marizyme's current stock value. Our valuation model uses many indicators to compare Marizyme value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Marizyme competition to find correlations between indicators driving Marizyme's intrinsic value. More Info.Marizyme is considered to be number one stock in return on equity category among its peers. It also is considered to be number one stock in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Marizyme's earnings, one of the primary drivers of an investment's value.Marizyme Return On Asset Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Marizyme's direct or indirect competition against its Return On Asset to detect undervalued stocks with similar characteristics or determine the otc stocks which would be a good addition to a portfolio. Peer analysis of Marizyme could also be used in its relative valuation, which is a method of valuing Marizyme by comparing valuation metrics of similar companies.Marizyme is currently under evaluation in return on asset category among its peers.
Marizyme Fundamentals
| Return On Equity | -0.5 | |||
| Return On Asset | -0.15 | |||
| Operating Margin | (180.85) % | |||
| Current Valuation | 17.35 M | |||
| Shares Outstanding | 10.13 M | |||
| Shares Owned By Insiders | 2.04 % | |||
| Price To Book | 0.37 X | |||
| Price To Sales | 133.06 X | |||
| Revenue | 210.28 K | |||
| Gross Profit | 129.93 K | |||
| EBITDA | (10.83 M) | |||
| Net Income | (11 M) | |||
| Cash And Equivalents | 2.04 M | |||
| Cash Per Share | 0.05 X | |||
| Total Debt | 495.32 K | |||
| Debt To Equity | 0.07 % | |||
| Current Ratio | 1.74 X | |||
| Book Value Per Share | 1.00 X | |||
| Cash Flow From Operations | (5.79 M) | |||
| Earnings Per Share | (0.39) X | |||
| Number Of Employees | 11 | |||
| Beta | 0.36 | |||
| Market Capitalization | 5.07 M | |||
| Total Asset | 66 M | |||
| Z Score | 6.0 | |||
| Net Asset | 66 M |
About Marizyme Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Marizyme's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Marizyme using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Marizyme based on its fundamental data. In general, a quantitative approach, as applied to this otc stock, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.Marizyme, Inc., a life science company, engages in the development and commercialization of medical technologies business. Marizyme, Inc. was incorporated in 2007 and is based in Jupiter, Florida. Marizyme operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 11 people.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectOther Information on Investing in Marizyme OTC Stock
Marizyme financial ratios help investors to determine whether Marizyme OTC Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Marizyme with respect to the benefits of owning Marizyme security.